Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota (SYN-ALD)
Profermin®: Prevention of Progression in Alcoholic Liver Disease by Modulating Dysbiotic Microbiota - a Randomized Controlled Clinical Trial
Sponsor: Nordisk Rebalance A/S
This NA trial investigates Alcoholic Liver Disease and Liver Cirrhosis, Alcoholic and is currently ongoing. Nordisk Rebalance A/S leads this study, which shows 11 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Active Not Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
-
Dec 2023 — Jul 2024 [monthly]
Active Not Recruiting NA
-
Sep 2022 — Dec 2023 [monthly]
Active Not Recruiting NA
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting NA
▶ Show 6 earlier versions
-
Oct 2021 — Jul 2022 [monthly]
Active Not Recruiting NA
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Sep 2021 [monthly]
Recruiting NA
-
Oct 2020 — Jan 2021 [monthly]
Recruiting NA
-
Jun 2019 — Oct 2020 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Apr 2019 — Jun 2019 [monthly]
Not Yet Recruiting NA
First recorded
Mar 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Nordisk Rebalance A/S
- Odense Patient Data Explorative Network
- Odense University Hospital
- Region of Southern Denmark
- University of Southern Denmark
For direct contact, visit the study record on ClinicalTrials.gov .